Quick answer
GLP-1 medications approved for weight management, Wegovy and Zepbound, are generally for adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. Eligibility also depends on the absence of contraindications and a physician's overall judgment. The diabetes versions, Ozempic and Mounjaro, are for people with type 2 diabetes. Qualifying is a medical determination made after an evaluation, not a self-assessment. These are prescription medications requiring physician supervision, and individual results vary.
What Are the BMI Criteria for a GLP-1?
For the weight-management products, the general criteria are a body mass index of 30 or higher (the obesity range), or 27 or higher (the overweight range) when accompanied by at least one weight-related health condition. Body mass index is a screening number based on height and weight, used as a starting point rather than the whole picture. These thresholds come from how the drugs were studied and approved for chronic weight management.
BMI is a gate, not the final word, because it does not capture everything about body composition or health. A physician uses it alongside your medical history, lab results, and weight-related conditions to decide whether treatment is appropriate. So meeting the BMI threshold makes you a candidate for evaluation, not automatically a prescription holder.
Do Weight-Related Conditions Change Eligibility?
Yes, significantly. If your BMI is in the overweight range (27 or higher) rather than the obesity range, having at least one weight-related health condition is what brings you into eligibility for weight-management GLP-1s. Common qualifying conditions include high blood pressure, type 2 diabetes, and high cholesterol, all of which are improved by weight loss and worsened by excess weight. The presence of these conditions strengthens the medical case for treatment.
This is also where weight-loss care connects to broader medical care, because these conditions need their own management. A clinician often evaluates them together, which is why weight-loss treatment is frequently coordinated with primary care. If you have type 2 diabetes specifically, that changes which products are most relevant, as covered in our guide on Ozempic vs Wegovy and on type 2 diabetes.
What Disqualifies Someone from a GLP-1?
Certain conditions are contraindications, meaning a GLP-1 should not be used. These include a personal or family history of medullary thyroid carcinoma or a syndrome called multiple endocrine neoplasia type 2, and a history of pancreatitis warrants caution. Pregnancy or planning pregnancy is also a reason not to use these drugs. Other medications, gastrointestinal conditions, and your overall health picture can make treatment inappropriate or require extra caution.
This screening is precisely why a medical evaluation is required and why these drugs are prescription-only. A physician reviews your personal and family history, current medications, and labs to rule out contraindications before prescribing. The screening protects you, which is why self-sourcing these drugs without an evaluation is unsafe.
How Do You Find Out If You Qualify?
You find out through a medical evaluation: a clinician reviews your height, weight, and BMI, your weight-related conditions, your full medical and family history, your current medications, and relevant labs, then makes a judgment about whether a GLP-1 is appropriate and which one. This is not something an online quiz or a self-check can settle, because eligibility hinges on contraindications and clinical context that require professional review.
The evaluation also sets up safe treatment if you do qualify, including the right product, the titration plan, and monitoring. Ascend's medical weight loss program runs that evaluation and supervises treatment. For a sense of what realistic results look like once you qualify, see our guide on semaglutide for weight loss.
Care at Ascend: Learn more about Weight Loss at Ascend Mind and Body, or book an appointment.
Frequently asked questions
Can I get a GLP-1 if my BMI is under 27?
Generally, no, for weight management, since the approved criteria for weight-management GLP-1s start at a BMI of 27 with a weight-related condition or 30 without one. The diabetes products follow different criteria tied to a diabetes diagnosis. A physician makes the final determination based on your full picture, but a BMI under 27 typically falls outside the approved use for weight management.
Do I qualify for Ozempic if I do not have diabetes?
Ozempic is approved for type 2 diabetes, so without diabetes you would generally be evaluated for a weight-management product like Wegovy instead, if you meet the criteria. A physician can prescribe a diabetes drug off label in some situations, but that is a case-by-case clinical decision. The approved path for weight management without diabetes is Wegovy or Zepbound.
Who decides if I qualify for a GLP-1 in Florida?
A licensed clinician in Florida decides, based on a medical evaluation of your BMI, weight-related conditions, medical and family history, medications, and labs. Eligibility is a medical determination, not a self-assessment, which is why these drugs require a prescription. The evaluation can often be done in person or, when appropriate, by telehealth.
Can I be evaluated for GLP-1 eligibility by telehealth in Florida?
Often, yes. Florida law allows a licensed clinician to establish care and evaluate eligibility by telehealth when it meets the standard of care, including reviewing your history and ordering labs. Whether a GLP-1 is appropriate still depends on that evaluation. Ascend offers this kind of evaluation as part of its weight-loss program.
Medically reviewed by
Dr. Jason Saylor, DO
This article is for general educational purposes only and is not medical advice. It does not create a provider-patient relationship. Talk with a qualified Florida-licensed clinician about your individual situation.
Sources
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prescription Medications to Treat Overweight and Obesity. niddk.nih.gov.
- U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. accessdata.fda.gov.
- U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. accessdata.fda.gov.